Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-17T10:09:55.232Z Has data issue: false hasContentIssue false

The Antibiotic Development Pipeline for Multidrug-Resistant Gram-Negative Bacilli: Current and Future Landscapes

Published online by Cambridge University Press:  02 January 2015

George H. Talbot*
Affiliation:
Talbot Advisors LLC, Wayne, Pennsylvania
*
PO Box 7440, St. Davids, PA 19087 (talbot@aya.yale.edu)

Abstract

Development of antibiotics to treat infections caused by multidrug-resistant gram-negative bacilli has lagged significantly behind development of antibiotics to treat infections with gram-positive pathogens. Although a few promising drugs have entered early clinical development, more must be done to preserve the utility of currently available antibiotics and to ensure a pipeline of efficacious, safe antibacterials.

Information

Type
Supplement Article
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable